Duke logo

Conatus 6556-14: Emricasan for NASH and Severe Portal Hypertension - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn whether a drug called emricasan can lower portal hypertension in patients with NASH

What is the Condition Being Studied?

Patients with non-alcoholic steatohepatitis (NASH) with portal high blood pressure who have participated in the IND-6556-14 study

Who Can Participate in the Study?

Adults 18-85 years of age who
- Have been diagnosed with Non Alcoholic Liver Cirrhosis
- Do not have cancer
- Are participating in the IND-6556-14 study

Contact the study team for more information

Age Group
Adults

What is Involved?

If you choose to join the study, you will:
- Continue in the same study group you were assigned to in the first 24 week study
-- Continue taking either Emricasan (the study drug) or placebo, whichever you were randomized to in the first part of the study for another 24 week
- Come for study visits every 8 weeks for physical exams, questionnaires, imaging exams, and lab tests

Study Details

Full Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis NASH) Cirrhosis and Severe Portal Hypertension
Principal Investigator
Protocol Number
IRB:PRO00075803
NCT:NCT02960204
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698